NCT07304674 The Association Between Primary Aldosteronism and Cognitive Dysfunction
| NCT ID | NCT07304674 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xinjiang Medical University |
| Condition | Primary Aldosteronism |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-12-31 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-12-31 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the prevalence, progression, and influencing factors of cognitive impairment in patients with primary aldosteronism (PA). The main questions it aims to answer are: 1. What is the prevalence of baseline cognitive impairment in PA patients and what factors are associated with it? 2. What is the incidence of cognitive progression in PA patients within 1 and 5 years of follow-up and what factors influence this progression? Participants who are already diagnosed with PA as part of their regular medical care will be invited to join this long-term study. They will complete regular cognitive tests, medical check-ups, and questionnaires for up to 5 years. Some participants will also have optional blood tests and brain scans to help researchers understand the causes behind any cognitive changes.
Eligibility Criteria
Inclusion Criteria: * 1\. Aged ≥ 40 years. * 2\. Biochemically confirmed diagnosis of Primary Aldosteronism (PA) according to contemporary guidelines (e.g., confirmed positive case detection test and confirmatory test). * 3\. Ability to understand and cooperate with comprehensive neuropsychological assessment. * 4\. Voluntary participation and provision of written informed consent. Exclusion Criteria: * 1\. Significant visual, hearing, or motor impairment that prevents completion of cognitive testing. * 2\. History of major neurological disorders (e.g., stroke, Parkinson's disease, intracranial tumor, severe traumatic brain injury). * 3\. History of major psychiatric illness, intellectual disability, or current use of antipsychotic medications. * 4\. Diagnosis of secondary hypertension other than PA. * 5\. Unwillingness to participate by the patient or their legal representative.
Contact & Investigator
Xiang Xie, PhD
STUDY CHAIR
First Affiliated Hospital of Xinjiang Medical University
Frequently Asked Questions
Who can join the NCT07304674 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Primary Aldosteronism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07304674 currently recruiting?
Yes, NCT07304674 is actively recruiting participants. Contact the research team at xiangxie999@sina.com for enrollment information.
Where is the NCT07304674 trial being conducted?
This trial is being conducted at Chengdu, China, Ürümqi, China.
Who is sponsoring the NCT07304674 clinical trial?
NCT07304674 is sponsored by Xinjiang Medical University. The principal investigator is Xiang Xie, PhD at First Affiliated Hospital of Xinjiang Medical University. The trial plans to enroll 1,000 participants.